Combine operations research with molecular biology to stretch pharmacogenomics and personalized medicine-A case study on HIV/AIDS

Autor(es)

Joly, Marcel ^{[1, 2, 3]} ; Pinto, Jose M. ^{[2, 4]} ; Rondo, Patricia H. C. ^[1] ; Rodrigues, Rosangela ^[5] ; Ferreira, Joao L. P. ^[5] ; Cavalcanti, Jaqueline S. ^[5] ; Brigido, Luis F. M. ^[5] ; Odloak, Darci ^[2]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Publ Hlth, BR-01246904 Sao Paulo, SP - Brazil

^[2] Univ Sao Paulo, Dept Chem Engn, BR-05508970 Sao Paulo, SP - Brazil

^[3] Petrobras Petr Brasileiro SA, Ctr Excellence Appl Ind Automat Technol, BR-05508970 Sao Paulo, SP - Brazil

^[4] Polytech Univ, Othmer Jacobs Dept Chem & Biol Engn, Metrotech Ctr 6, Brooklyn, NY 11201 - USA

^[5] Adolfo Lutz Inst Sao Paulo, Virol Ctr, Retrovirus Lab, BR-01246902 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Computers & Chemical Engineering; v. 80, p. 114-129, SEP 2 2015.
• Citações Web of Science: 4

Resumo

The dramatic reduction in morbidity and mortality associated with the use of highly active antiretroviral therapy has created new challenges for clinicians: AIDS has become a chronic, potentially life-threatening, condition in many clinical instances. In this paper, a novel system engineering approach based on mixed-integer linear programming (MILP) is presented to support HIV/AIDS clinicians when formulating real-world therapeutic plans for heavily treatment-experienced patients under variable settings. Our results suggest that, while current practices (standard protocols and/or subjective recommendations based on the clinician's experience) can generally provide satisfactory management of drug resistance in the short-term, optimization-based therapy planning has a far greater potential to achieve this goal over expanded time horizons thereby changing paradigms and rethinking best practices in the HIV/AIDS clinical arena. Moreover, the ability of this methodology to address other viral pathologies (e.g., hepatitis B and C virus) can make this work appeal to a broader audience. (C) 2015 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 99/09897-4 - Metodologias para a operação de Scheduling ótimos de sistemas reativos em batelada
• Beneficiário: Marcel Joly
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 11/21958-2 - Resistência genotípica no resgate terapêutico de pacientes infectados pelo HIV-1 com novas classes de antirretrovirais
• Beneficiário: Luís Fernando de Macedo Brígido
• Linha de fomento: Auxílio à Pesquisa - Regular